Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 20 | 2025 | 272 | 7.870 |
Why?
|
| Electronic Nicotine Delivery Systems | 26 | 2025 | 84 | 7.390 |
Why?
|
| Tobacco Products | 22 | 2024 | 80 | 6.120 |
Why?
|
| Vaping | 14 | 2025 | 53 | 4.450 |
Why?
|
| Cigarette Smoking | 10 | 2025 | 48 | 3.950 |
Why?
|
| Social Media | 12 | 2024 | 111 | 3.410 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 11 | 2020 | 74 | 2.870 |
Why?
|
| Affect | 11 | 2025 | 397 | 2.540 |
Why?
|
| Substance Withdrawal Syndrome | 8 | 2024 | 53 | 2.520 |
Why?
|
| Oxytocin | 6 | 2024 | 75 | 2.220 |
Why?
|
| Marketing | 7 | 2022 | 24 | 2.210 |
Why?
|
| Methamphetamine | 9 | 2021 | 104 | 2.170 |
Why?
|
| Tobacco Use Disorder | 8 | 2024 | 122 | 2.040 |
Why?
|
| Central Nervous System Stimulants | 12 | 2018 | 235 | 1.900 |
Why?
|
| Mindfulness | 2 | 2024 | 19 | 1.690 |
Why?
|
| Emotions | 7 | 2017 | 377 | 1.580 |
Why?
|
| Hallucinogens | 6 | 2016 | 84 | 1.470 |
Why?
|
| Social Behavior | 9 | 2023 | 309 | 1.460 |
Why?
|
| Administration, Intranasal | 10 | 2024 | 140 | 1.340 |
Why?
|
| Ethanol | 4 | 2021 | 270 | 1.330 |
Why?
|
| Tobacco Industry | 3 | 2024 | 8 | 1.320 |
Why?
|
| Young Adult | 39 | 2025 | 7001 | 1.300 |
Why?
|
| Flavoring Agents | 6 | 2021 | 12 | 1.290 |
Why?
|
| Nicotine | 11 | 2025 | 210 | 1.240 |
Why?
|
| Video Games | 2 | 2021 | 12 | 1.240 |
Why?
|
| Motivation | 8 | 2022 | 310 | 1.200 |
Why?
|
| Dextroamphetamine | 6 | 2018 | 108 | 1.180 |
Why?
|
| Depression | 6 | 2025 | 560 | 1.160 |
Why?
|
| Smokers | 4 | 2021 | 55 | 1.070 |
Why?
|
| Double-Blind Method | 22 | 2020 | 1794 | 1.060 |
Why?
|
| Adult | 50 | 2025 | 28637 | 1.050 |
Why?
|
| Substance-Related Disorders | 9 | 2023 | 451 | 1.010 |
Why?
|
| Smoking | 11 | 2023 | 650 | 1.000 |
Why?
|
| Humans | 95 | 2025 | 95971 | 1.000 |
Why?
|
| Psychomotor Performance | 7 | 2011 | 505 | 0.990 |
Why?
|
| Adolescent | 34 | 2025 | 9888 | 0.920 |
Why?
|
| Male | 59 | 2025 | 45735 | 0.900 |
Why?
|
| Underage Drinking | 3 | 2021 | 3 | 0.880 |
Why?
|
| Adolescent Behavior | 7 | 2020 | 115 | 0.860 |
Why?
|
| Social Facilitation | 2 | 2021 | 8 | 0.850 |
Why?
|
| Female | 59 | 2025 | 49938 | 0.840 |
Why?
|
| Students | 5 | 2021 | 179 | 0.830 |
Why?
|
| Tobacco Use Cessation | 1 | 2023 | 9 | 0.810 |
Why?
|
| Dehydroepiandrosterone | 1 | 2023 | 50 | 0.810 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 192 | 0.770 |
Why?
|
| Mobile Applications | 1 | 2023 | 81 | 0.750 |
Why?
|
| Tobacco Use | 7 | 2022 | 31 | 0.740 |
Why?
|
| Heart Rate | 6 | 2016 | 519 | 0.710 |
Why?
|
| Blood Pressure | 7 | 2016 | 929 | 0.700 |
Why?
|
| Binge Drinking | 1 | 2021 | 15 | 0.680 |
Why?
|
| Self Efficacy | 1 | 2021 | 61 | 0.670 |
Why?
|
| Risk-Taking | 2 | 2021 | 163 | 0.660 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2012 | 29 | 0.650 |
Why?
|
| Healthy Volunteers | 5 | 2018 | 157 | 0.650 |
Why?
|
| Sleep | 4 | 2011 | 458 | 0.640 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 2 | 2010 | 11 | 0.630 |
Why?
|
| Consumer Behavior | 1 | 2019 | 32 | 0.610 |
Why?
|
| Cognition | 6 | 2015 | 635 | 0.610 |
Why?
|
| Behavior, Addictive | 3 | 2023 | 137 | 0.600 |
Why?
|
| Analgesics, Opioid | 5 | 2025 | 512 | 0.590 |
Why?
|
| Personality | 3 | 2015 | 140 | 0.570 |
Why?
|
| Amphetamine | 2 | 2016 | 102 | 0.560 |
Why?
|
| Health Education | 1 | 2018 | 107 | 0.560 |
Why?
|
| Attitude to Health | 2 | 2018 | 227 | 0.550 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2016 | 1969 | 0.550 |
Why?
|
| Social Networking | 1 | 2018 | 85 | 0.550 |
Why?
|
| Impulsive Behavior | 3 | 2019 | 290 | 0.520 |
Why?
|
| Music | 3 | 2022 | 35 | 0.520 |
Why?
|
| Surveys and Questionnaires | 13 | 2021 | 2863 | 0.520 |
Why?
|
| Social Environment | 2 | 2016 | 195 | 0.510 |
Why?
|
| Marijuana Use | 3 | 2020 | 12 | 0.480 |
Why?
|
| Individuality | 2 | 2018 | 114 | 0.480 |
Why?
|
| California | 3 | 2025 | 161 | 0.470 |
Why?
|
| Choice Behavior | 3 | 2014 | 165 | 0.440 |
Why?
|
| Serotonin Agents | 1 | 2014 | 13 | 0.430 |
Why?
|
| Empathy | 2 | 2015 | 155 | 0.420 |
Why?
|
| Intention | 3 | 2022 | 52 | 0.400 |
Why?
|
| Alcoholic Intoxication | 1 | 2013 | 37 | 0.390 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2013 | 44 | 0.380 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 1875 | 0.370 |
Why?
|
| Parents | 2 | 2025 | 307 | 0.350 |
Why?
|
| Self Report | 7 | 2022 | 328 | 0.350 |
Why?
|
| Sex Factors | 2 | 2024 | 1132 | 0.340 |
Why?
|
| Eating | 1 | 2011 | 165 | 0.330 |
Why?
|
| Neoplasms | 2 | 2023 | 3246 | 0.330 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 287 | 0.330 |
Why?
|
| Hypnotics and Sedatives | 2 | 2013 | 142 | 0.320 |
Why?
|
| Health Behavior | 2 | 2022 | 191 | 0.320 |
Why?
|
| Reward | 5 | 2019 | 209 | 0.290 |
Why?
|
| Pyridines | 1 | 2010 | 319 | 0.280 |
Why?
|
| Los Angeles | 5 | 2020 | 30 | 0.270 |
Why?
|
| Internal-External Control | 1 | 2007 | 45 | 0.270 |
Why?
|
| Speech | 2 | 2020 | 91 | 0.260 |
Why?
|
| Psychotropic Drugs | 2 | 2020 | 82 | 0.260 |
Why?
|
| Self Administration | 3 | 2012 | 76 | 0.250 |
Why?
|
| Anxiety Disorders | 3 | 2019 | 156 | 0.250 |
Why?
|
| Arousal | 3 | 2018 | 173 | 0.240 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 649 | 0.230 |
Why?
|
| Exercise | 2 | 2020 | 354 | 0.230 |
Why?
|
| Pamphlets | 1 | 2025 | 14 | 0.230 |
Why?
|
| Anxiety | 2 | 2019 | 339 | 0.220 |
Why?
|
| Awareness | 1 | 2025 | 90 | 0.220 |
Why?
|
| Nicotine Chewing Gum | 1 | 2024 | 3 | 0.220 |
Why?
|
| Administration, Oral | 4 | 2018 | 690 | 0.220 |
Why?
|
| Hostility | 1 | 2024 | 25 | 0.220 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2023 | 16 | 0.210 |
Why?
|
| Middle Aged | 8 | 2025 | 28255 | 0.210 |
Why?
|
| Attentional Bias | 1 | 2023 | 10 | 0.210 |
Why?
|
| United States | 8 | 2025 | 7762 | 0.210 |
Why?
|
| Product Labeling | 2 | 2013 | 3 | 0.200 |
Why?
|
| Alkaloids | 2 | 2013 | 46 | 0.200 |
Why?
|
| Buprenorphine | 1 | 2024 | 51 | 0.200 |
Why?
|
| Pain Management | 1 | 2025 | 180 | 0.200 |
Why?
|
| Drug Overdose | 1 | 2024 | 89 | 0.190 |
Why?
|
| Schools | 2 | 2020 | 84 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 155 | 0.190 |
Why?
|
| Marijuana Smoking | 2 | 2019 | 28 | 0.180 |
Why?
|
| Patient Education as Topic | 1 | 2025 | 381 | 0.180 |
Why?
|
| Pain, Postoperative | 2 | 2021 | 278 | 0.180 |
Why?
|
| Racism | 1 | 2023 | 105 | 0.170 |
Why?
|
| Smoke | 1 | 2021 | 29 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 570 | 0.170 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2021 | 66 | 0.170 |
Why?
|
| Internet | 2 | 2020 | 339 | 0.160 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 232 | 0.160 |
Why?
|
| Premenopause | 1 | 2020 | 63 | 0.160 |
Why?
|
| Pain | 2 | 2024 | 423 | 0.160 |
Why?
|
| Plants, Edible | 1 | 2019 | 2 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 98 | 0.160 |
Why?
|
| Product Packaging | 1 | 2019 | 1 | 0.160 |
Why?
|
| Government Regulation | 1 | 2019 | 50 | 0.160 |
Why?
|
| Mood Disorders | 1 | 2020 | 83 | 0.160 |
Why?
|
| Aromatherapy | 1 | 2019 | 1 | 0.160 |
Why?
|
| Work Schedule Tolerance | 2 | 2010 | 37 | 0.160 |
Why?
|
| Taste | 1 | 2019 | 29 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 113 | 0.150 |
Why?
|
| Cannabis | 1 | 2019 | 40 | 0.150 |
Why?
|
| Behavior Therapy | 1 | 2020 | 95 | 0.150 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2019 | 62 | 0.150 |
Why?
|
| Pleasure | 2 | 2015 | 14 | 0.150 |
Why?
|
| Cartoons as Topic | 1 | 2018 | 3 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2019 | 936 | 0.140 |
Why?
|
| Commerce | 1 | 2018 | 31 | 0.140 |
Why?
|
| Language | 1 | 2020 | 161 | 0.140 |
Why?
|
| Economics, Behavioral | 1 | 2018 | 7 | 0.140 |
Why?
|
| Attitude | 1 | 2018 | 137 | 0.140 |
Why?
|
| Risk Factors | 6 | 2020 | 5949 | 0.140 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 549 | 0.140 |
Why?
|
| Drug Interactions | 2 | 2015 | 246 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2018 | 391 | 0.140 |
Why?
|
| Anhedonia | 1 | 2017 | 13 | 0.130 |
Why?
|
| Progesterone | 1 | 2017 | 112 | 0.130 |
Why?
|
| Health Promotion | 1 | 2018 | 176 | 0.130 |
Why?
|
| Patient Selection | 1 | 2021 | 708 | 0.130 |
Why?
|
| Designer Drugs | 2 | 2013 | 4 | 0.130 |
Why?
|
| Estradiol | 1 | 2017 | 256 | 0.130 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 44 | 0.120 |
Why?
|
| Comorbidity | 2 | 2017 | 1006 | 0.120 |
Why?
|
| Principal Component Analysis | 2 | 2016 | 168 | 0.120 |
Why?
|
| Premenstrual Syndrome | 1 | 2016 | 2 | 0.120 |
Why?
|
| Self-Control | 1 | 2016 | 12 | 0.120 |
Why?
|
| Receptors, Oxytocin | 1 | 2016 | 10 | 0.120 |
Why?
|
| Neuropeptides | 1 | 2016 | 116 | 0.120 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2016 | 36 | 0.120 |
Why?
|
| Panic Disorder | 1 | 2015 | 21 | 0.120 |
Why?
|
| Neurotransmitter Agents | 1 | 2016 | 111 | 0.120 |
Why?
|
| Craving | 1 | 2016 | 24 | 0.120 |
Why?
|
| Visual Analog Scale | 1 | 2015 | 17 | 0.120 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2015 | 30 | 0.120 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 397 | 0.120 |
Why?
|
| Cadherins | 1 | 2016 | 180 | 0.120 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 87 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2021 | 4663 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2015 | 504 | 0.110 |
Why?
|
| Social Class | 1 | 2015 | 145 | 0.110 |
Why?
|
| Focus Groups | 2 | 2025 | 191 | 0.100 |
Why?
|
| Time Factors | 2 | 2014 | 5577 | 0.100 |
Why?
|
| Genome-Wide Association Study | 3 | 2016 | 1763 | 0.100 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2013 | 7 | 0.100 |
Why?
|
| Drug and Narcotic Control | 1 | 2013 | 7 | 0.100 |
Why?
|
| Diphenhydramine | 1 | 2013 | 16 | 0.100 |
Why?
|
| Breath Tests | 1 | 2013 | 58 | 0.100 |
Why?
|
| Depressive Disorder, Major | 1 | 2015 | 174 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 2494 | 0.100 |
Why?
|
| Alcoholism | 1 | 2015 | 191 | 0.100 |
Why?
|
| Emergency Treatment | 1 | 2013 | 47 | 0.100 |
Why?
|
| Euphoria | 1 | 2013 | 47 | 0.100 |
Why?
|
| Photic Stimulation | 2 | 2014 | 514 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 456 | 0.100 |
Why?
|
| Linear Models | 1 | 2014 | 438 | 0.100 |
Why?
|
| Fear | 1 | 2013 | 87 | 0.090 |
Why?
|
| Psychomotor Disorders | 1 | 2012 | 20 | 0.090 |
Why?
|
| New York | 1 | 2012 | 76 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2015 | 345 | 0.090 |
Why?
|
| HIV Infections | 1 | 2021 | 975 | 0.090 |
Why?
|
| United States Food and Drug Administration | 2 | 2024 | 146 | 0.090 |
Why?
|
| Research Design | 1 | 2015 | 631 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2023 | 10190 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2876 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1805 | 0.080 |
Why?
|
| Work | 1 | 2010 | 15 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2012 | 200 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2014 | 780 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2023 | 3093 | 0.070 |
Why?
|
| Administration, Cutaneous | 2 | 2020 | 61 | 0.070 |
Why?
|
| Wakefulness | 1 | 2008 | 137 | 0.070 |
Why?
|
| Adrenergic Agents | 1 | 2007 | 6 | 0.070 |
Why?
|
| Fatigue | 1 | 2008 | 185 | 0.070 |
Why?
|
| Behavior | 1 | 2007 | 87 | 0.070 |
Why?
|
| Orientation | 1 | 2007 | 119 | 0.070 |
Why?
|
| Homosexuality | 1 | 1987 | 10 | 0.070 |
Why?
|
| Judgment | 1 | 2007 | 70 | 0.060 |
Why?
|
| Mother-Child Relations | 1 | 1987 | 31 | 0.060 |
Why?
|
| Maternal Behavior | 1 | 1987 | 56 | 0.060 |
Why?
|
| Pattern Recognition, Visual | 1 | 2007 | 162 | 0.060 |
Why?
|
| Selection, Genetic | 1 | 1990 | 537 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 777 | 0.060 |
Why?
|
| Models, Genetic | 1 | 1990 | 983 | 0.060 |
Why?
|
| Chewing Gum | 1 | 2024 | 4 | 0.050 |
Why?
|
| Heroin | 1 | 2024 | 14 | 0.050 |
Why?
|
| Psychometrics | 2 | 2015 | 340 | 0.050 |
Why?
|
| Baths | 2 | 2013 | 10 | 0.050 |
Why?
|
| Salts | 2 | 2013 | 18 | 0.050 |
Why?
|
| Multifactorial Inheritance | 2 | 2015 | 201 | 0.050 |
Why?
|
| Fentanyl | 1 | 2024 | 87 | 0.050 |
Why?
|
| Menthol | 1 | 2022 | 5 | 0.050 |
Why?
|
| Ice | 1 | 2022 | 11 | 0.050 |
Why?
|
| Biological Evolution | 1 | 1990 | 1030 | 0.050 |
Why?
|
| Laboratories | 1 | 2022 | 48 | 0.040 |
Why?
|
| Needle Sharing | 1 | 2021 | 15 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3901 | 0.040 |
Why?
|
| Psycholinguistics | 1 | 2020 | 10 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 152 | 0.040 |
Why?
|
| Adolescent Health | 1 | 2019 | 5 | 0.040 |
Why?
|
| Semantics | 1 | 2020 | 55 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 174 | 0.040 |
Why?
|
| Temperament | 1 | 2019 | 28 | 0.040 |
Why?
|
| Tobacco, Smokeless | 1 | 2018 | 10 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2019 | 226 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2018 | 166 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2016 | 25 | 0.030 |
Why?
|
| Diet | 1 | 2020 | 461 | 0.030 |
Why?
|
| Saliva | 1 | 2017 | 128 | 0.030 |
Why?
|
| Ovary | 1 | 2017 | 268 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1963 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2019 | 594 | 0.030 |
Why?
|
| Ganglionic Stimulants | 1 | 2015 | 7 | 0.030 |
Why?
|
| Placebos | 1 | 2016 | 213 | 0.030 |
Why?
|
| Cell Phone | 1 | 2016 | 39 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 683 | 0.030 |
Why?
|
| Neuroticism | 1 | 2015 | 5 | 0.030 |
Why?
|
| Guanylate Kinases | 1 | 2015 | 12 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 71 | 0.030 |
Why?
|
| Anticipation, Psychological | 1 | 2015 | 10 | 0.030 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2015 | 17 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 382 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 176 | 0.030 |
Why?
|
| Child | 2 | 2021 | 7624 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 817 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 382 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 912 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 91 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2015 | 182 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 9092 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1096 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 307 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 711 | 0.030 |
Why?
|
| Social Marketing | 1 | 2013 | 11 | 0.030 |
Why?
|
| Poison Control Centers | 1 | 2013 | 19 | 0.030 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2013 | 53 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2015 | 221 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 213 | 0.020 |
Why?
|
| Visual Perception | 1 | 2014 | 339 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 7205 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 1990 | 339 | 0.020 |
Why?
|
| Child Rearing | 1 | 1987 | 6 | 0.020 |
Why?
|
| Father-Child Relations | 1 | 1987 | 10 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2007 | 224 | 0.020 |
Why?
|
| Gender Identity | 1 | 1987 | 60 | 0.020 |
Why?
|
| Psychotherapy | 1 | 1987 | 73 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2473 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 312 | 0.010 |
Why?
|
| Life Style | 1 | 1987 | 186 | 0.010 |
Why?
|
| Social Support | 1 | 1987 | 239 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 20877 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1987 | 3977 | 0.010 |
Why?
|
| Animals | 1 | 1990 | 28924 | 0.010 |
Why?
|